Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nadege T Gunn

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Gastroenterology & Hepatology|May 26, 2021
Lean Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver DiseaseNadege T Gunn
Clinics in Liver Disease|November 13, 2017
The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in WhomNadege T Gunn, Mitchell L Shiffman
Liver International : Official Journal of the International Association for the Study of the Liver|January 5, 2017
Impact of hepatitis C virus therapy on metabolism and public healthMitchell L Shiffman, Nadege T Gunn
Clinical Liver Disease|April 18, 2019
Developing a relationship with a liver transplant programMitchell L Shiffman, Nadege T Gunn
Gastro Hep Advances|June 15, 2026
Assessment of Esophageal and Gastric Varices in Patients With Cirrhosis for Clinical Trials: A Centralized Blinded Evaluation SystemNaim Alkhouri, Raj Vuppalanchi, Mazen Noureddin, et al.
The American Journal of Gastroenterology|August 12, 2021
Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver DiseaseStephen A Harrison, Seth J Baum, Nadege T Gunn, et al.
Hepatology (Baltimore, Md.)|May 1, 2026
Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trialNaga Chalasani, Raj Vuppalanchi, Mazen Noureddin, et al.
Gastroenterology|August 12, 2020
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic SteatohepatitisStephen A Harrison, Guy Neff, Cynthia D Guy, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Gastroenterology & Hepatology|May 26, 2021
Lean Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver DiseaseNadege T Gunn
Clinics in Liver Disease|November 13, 2017
The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in WhomNadege T Gunn, Mitchell L Shiffman
Liver International : Official Journal of the International Association for the Study of the Liver|January 5, 2017
Impact of hepatitis C virus therapy on metabolism and public healthMitchell L Shiffman, Nadege T Gunn
Clinical Liver Disease|April 18, 2019
Developing a relationship with a liver transplant programMitchell L Shiffman, Nadege T Gunn
Gastro Hep Advances|June 15, 2026
Assessment of Esophageal and Gastric Varices in Patients With Cirrhosis for Clinical Trials: A Centralized Blinded Evaluation SystemNaim Alkhouri, Raj Vuppalanchi, Mazen Noureddin, et al.
The American Journal of Gastroenterology|August 12, 2021
Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver DiseaseStephen A Harrison, Seth J Baum, Nadege T Gunn, et al.
Hepatology (Baltimore, Md.)|May 1, 2026
Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trialNaga Chalasani, Raj Vuppalanchi, Mazen Noureddin, et al.
Gastroenterology|August 12, 2020
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic SteatohepatitisStephen A Harrison, Guy Neff, Cynthia D Guy, et al.
Pageof 1